TransMedics selloff despite CEO insider buying and durable growth

Conviction: 68% · Horizon: 2Y · 2026-07-14
Market misprices insider conviction and a historically rare sub-4x NTM revenue multiple

Shares have fallen roughly one-third since the CEO purchased about three million dollars of stock, even as the company guides to roughly twenty-two percent revenue growth in fiscal 2026. The stock has not previously traded below four times next-twelve-months revenue, suggesting the current pullback may be sentiment-driven rather than fundamental.

Instrument Side Target Reason
TMDX Long Insider purchases at scale, revenue growth near twenty-two percent, and a valuation that has not historically breached four times NTM sales together argue for mean reversion once near-term fear fades.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.